Want to see JP:2370 full AI Analyst Report?
Top Page
MEDINET Co., Ltd.
(2370)
Select Model
Select Model
Rating:45Neutral
Price Target:
¥24.50
▼(-15.52% Downside)
Action:Reiterated
Date:08/06/26
The score is held down primarily by persistent, very large losses and worsening cash burn (with declining equity despite low leverage). Technical indicators are broadly neutral with a longer-term downtrend, and valuation is difficult to support given a negative P/E and no dividend yield data.
Positive Factors
Low leverage
The company’s effectively zero debt profile materially reduces near-term solvency risk and preserves financial flexibility. Over the next several months this supports the ability to fund operations, pursue client contracts or restructure financing without pressure from interest costs or covenant constraints.
Negative Factors
Severe cash burn
Persistent negative operating and free cash flow means reported losses translate into real liquidity outflows, eroding runway. Over a multi-month horizon this raises the likelihood of needing external financing, which can dilute shareholders or constrain investment in operational improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
The company’s effectively zero debt profile materially reduces near-term solvency risk and preserves financial flexibility. Over the next several months this supports the ability to fund operations, pursue client contracts or restructure financing without pressure from interest costs or covenant constraints.
Read all positive factors
MEDINET Co., Ltd. (2370) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥7.04B
Dividend YieldN/A
Average Volume (3M)1.57M
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue Growth5.94%
EPS Growth12.09%
CountryJP
Employees107
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.29
Shares Outstanding281,667,330
10 Day Avg. Volume1,137,840
30 Day Avg. Volume1,567,416
Financial Highlights & Ratios
PEG Ratio-3.11
Price to Book (P/B)2.45
Price to Sales (P/S)11.43
P/FCF Ratio-6.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MEDINET Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1995 and headquartered in Tokyo, Japan, MEDINET Co., Ltd. functions as a contract development and manufacturing organization (CDMO) primarily focused on regenerative medicine and cell therapy solutions within Japan. The company furn...
How the Company Makes Money
MEDINET makes money primarily by providing fee-based services to organizations conducting medical research (e.g., pharmaceutical companies, medical institutions, and/or research organizations). Revenue is generated from contracts for clinical rese...
MEDINET Co., Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
15
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 724.63M | 810.29M | 768.50M | 661.54M | 633.67M | 683.03M |
| Gross Profit | 128.40M | 83.44M | 82.67M | 65.21M | 90.44M | 135.45M |
| EBITDA | -1.29B | -1.26B | -1.20B | -1.36B | -1.17B | -718.52M |
| Net Income | -1.41B | -1.36B | -1.28B | -1.44B | -1.25B | -843.40M |
Balance Sheet | ||||||
| Total Assets | 6.35B | 4.25B | 5.70B | 5.63B | 6.08B | 5.38B |
| Cash, Cash Equivalents and Short-Term Investments | 5.03B | 3.17B | 4.65B | 4.40B | 4.50B | 4.10B |
| Total Debt | 91.32M | 0.00 | 781.00K | 2.31M | 4.30M | 7.69M |
| Total Liabilities | 548.63M | 477.10M | 509.95M | 590.60M | 566.58M | 475.44M |
| Stockholders Equity | 5.80B | 3.78B | 5.19B | 5.04B | 5.51B | 4.90B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.44B | -1.25B | -1.28B | -1.14B | -633.51M |
| Operating Cash Flow | 0.00 | -1.41B | -1.19B | -1.26B | -1.13B | -612.08M |
| Investing Cash Flow | 0.00 | -565.17M | -12.71M | -2.16M | -50.35M | -18.38M |
| Financing Cash Flow | 0.00 | -2.55M | 1.46B | 1.16B | 1.58B | 1.08B |
MEDINET Co., Ltd. Technical Analysis
Negative
29.00
Price Trends
25.14
Negative
27.03
Negative
29.27
Negative
Market Momentum
0.05
Negative
50.21
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2370, the sentiment is Negative. The current price of 29 is above the 20-day moving average (MA) of 24.80, above the 50-day MA of 25.14, and below the 200-day MA of 29.27, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 50.21 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2370.
MEDINET Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | ¥5.60B | 30.40 | ― | 2.08% | -11.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥4.65B | -1.40 | ― | 5.44% | -16.97% | -517.61% | |
45 Neutral | ¥7.04B | -5.51 | ― | ― | 5.94% | 12.09% | |
44 Neutral | ¥5.73B | -5.93 | ― | ― | 74.13% | 22.94% | |
43 Neutral | ¥3.54B | -45.34 | ― | ― | 1.30% | 92.91% |
* Healthcare Sector Average
JP:2370
MEDINET Co., Ltd.
25.00
-13.00
-34.21%
JP:2183
Linical Co., Ltd.
210.00
-117.87
-35.95%
JP:2342
Trans Genic Inc.
221.00
17.00
8.33%
JP:2385
Soiken Holdings Inc.
217.00
54.90
33.87%
JP:206A
PRISM BioLab Co. LTD
160.00
-22.00
-12.09%
MEDINET Co., Ltd. Corporate Events
MEDINET Narrows Losses on Modest Sales Growth but Keeps Dividend at Zero
May 13, 2026
MEDINET Co., Ltd. reported net sales of ¥414 million for the six months ended March 2026, a 2.3% year-on-year increase, while operating and ordinary losses narrowed to ¥629 million and ¥516 million, respectively, resulting in a net ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.